Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Taltirelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR known ✓ | P34981 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taltirelin SCHEMBL30892167 | 1.00 | TRHR (0.72) | TRHR | |
| Taltirelin SCHEMBL194528 | 0.99 | TRHR (0.73) | TRHR | |
| Taltirelin SCHEMBL13993039 | 0.99 | TRHR (0.73) | TRHR | |
| Taltirelin SCHEMBL2320945 | 0.95 | TRHR (0.69) | TRHR | |
| Azetirelin SCHEMBL195158 | 0.90 | TRHR (0.85) | TRHR | |
| Taltirelin SCHEMBL2321397 | 0.90 | TRHR (0.61) | TRHR | |
| Taltirelin SCHEMBL22077031 | 0.85 | TRHR (0.65) | TRHR | |
| Taltirelin SCHEMBL3188420 | 0.85 | TRHR (0.57) | TRHR | |
| Taltirelin SCHEMBL21219549 | 0.84 | TRHR (0.57) | TRHR | |
| Taltirelin SCHEMBL21219551 | 0.84 | TRHR (0.57) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20240122860-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| WO-2024079739-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20240122847-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| WO-2024079738-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | claimed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | claimed |
| CN-102223880-B | Oral quick disintegrating tablet and its preparation method | 田边三菱制药株式会社 | 2017-04-26 | — | — | CN | claimed |
| CN-103919742-B | Orally Rapidly Disintegrating Tablet And Process For Producing Same | 田边三菱制药株式会社 | 2017-04-12 | — | — | CN | claimed |
| EP-2808013-A1 | Orally rapidly disintegrating tablet and process for producing same | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-12-03 | — | — | EP | claimed |
| CN-103919742-A | Orally Rapidly Disintegrating Tablet And Process For Producing Same | MITSUBISHI TANABE PHARMA CORP | 2014-07-16 | — | — | CN | claimed |
| CN-102988318-A | Orally rapidly disintegrating tablet and process for producing same | MITSUBISHI TANABE PHARMA CORP | 2013-03-27 | — | — | CN | claimed |
| CN-102223880-A | Oral quick disintegrating tablet and its preparation method | MITSUBISHI TANABE PHARMA CORP | 2011-10-19 | — | — | CN | claimed |
| EP-2368544-A1 | ORALLY RAPIDLY DISINTEGRATING TABLET, AND PROCESS FOR PRODUCING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-28 | — | — | EP | claimed |
| US-20110229570-A1 | ORALLY RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR PRODUCING SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-22 | — | — | US | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | disclosed |
| US-12582606-B2 | Tablet and method for producing tablet | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| EP-3777858-B1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | TORAY INDUSTRIES (JP) | 2025-04-02 | — | — | EP | disclosed |
| US-12257352-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-03-25 | — | — | US | disclosed |
| CN-119677502-A | Drotaverine orally disintegrating palatable preparation and preparation method thereof | 德罗塔斯塔有限责任公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| EP-4408480-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240122860-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | disclosed |
| US-20240122847-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | disclosed |
| WO-2024079739-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024079738-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | disclosed |
| US-20240091367-A1 | ORALLY DISINTEGRATING PALATABLE FORMULATIONS OF DROTAVERINE AND METHOD OF PREPARATION THEREOF | SUSHMA PAUL BERLIA (IN) | 2024-03-21 | — | — | US | disclosed |
| WO-2024023786-A1 | ORALLY DISINTEGRATING PALATABLE FORMULATIONS OF DROTAVERINE AND METHOD OF PREPARATION THEREOF | BERLIA SUSHMA PAUL (IN) | 2024-02-01 | — | — | WO | disclosed |
| CN-111902143-B | Inhibitors of calcium concentration increase in nerve cells | 东丽株式会社 | 2024-01-02 | — | — | CN | disclosed |
| EP-4228657-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116390764-A | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses | 密歇根大学董事会 | 2023-07-04 | — | — | CN | disclosed |
| EP-3520795-B1 | COMPOSITION COMPRISING COMBINATION OF TRH ANALOG WITH ARUNDIC ACID, AND PHARMACEUTICALLY ACCEPTABLE SALT OF ARUNDIC ACID | BRIVENTION PHARMACEUTICAL SHANGHAI INC (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20230135373-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2023-05-04 | — | — | US | disclosed |
| WO-2023056427-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | disclosed |
| CN-113559102-B | Compositions comprising a combination of a TRH analogue and propyloctanoic acid and pharmaceutically acceptable salts of propyloctanoic acid | 布利本迅药业(上海)有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-11510914-B2 | Agent for inhibiting rise in intraneuronal calcium concentration | TORAY INDUSTRIES, INC. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20220218616-A1 | TABLET AND METHOD FOR PRODUCING TABLET | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| WO-2022081993-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| CN-113559102-A | Compositions comprising a combination of a TRH analogue and propyloctanoic acid and pharmaceutically acceptable salts of propyloctanoic acid | 布利本迅药业(上海)有限公司 | 2021-10-29 | — | — | CN | disclosed |
| WO-2021202906-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2021-10-07 | — | — | WO | disclosed |
| CN-110267661-B | Compositions comprising a combination of a TRH analogue and propyloctanoic acid and pharmaceutically acceptable salts of propyloctanoic acid | 布利本迅药业(上海)有限公司 | 2021-08-03 | — | — | CN | disclosed |
| WO-2021119439-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF BCL-2 AND BCL-XL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3315128-B1 | DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION | SHIONOGI & CO (JP) | 2021-05-19 | — | — | EP | disclosed |
| EP-3820534-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | disclosed |
| EP-3777858-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | Toray Industries, Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210023068-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | TORAY INDUSTRIES, INC. (JP) | 2021-01-28 | — | — | US | disclosed |
| US-10828303-B2 | Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid | Brivention Pharmaceutical (Shanghai) Inc. (CN) | 2020-11-10 | — | — | US | disclosed |
| WO-2020213589-A1 | TABLET AND METHOD FOR PRODUCING TABLET | 三生医薬株式会社 | 2020-10-22 | — | — | WO | disclosed |
| CN-110267661-A | Compositions comprising a combination of a TRH analogue and propyloctanoic acid and pharmaceutically acceptable salts of propyloctanoic acid | 布利本迅药业(上海)有限公司 | 2019-09-20 | — | — | CN | disclosed |
| US-20190240221-A1 | COMPOSITION COMPRISING COMBINATION OF TRH ANALOG WITH ARUNDIC ACID, AND PHARMACEUTICALLY ACCEPTABLE SALT OF ARUNDIC ACID | Brivention Pharmaceutical (Shanghai) Inc. (CN) | 2019-08-08 | — | — | US | disclosed |
| EP-3520795-A1 | COMPOSITION COMPRISING COMBINATION OF TRH ANALOG WITH ARUNDIC ACID, AND PHARMACEUTICALLY ACCEPTABLE SALT OF ARUNDIC ACID | Brivention Pharmaceutical (Shanghai) Inc. (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-105377303-B | Oral disnitegration tablet | 株式会社三和化学研究所 | 2019-04-05 | — | — | CN | disclosed |
| EP-3075738-B1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | INI CORP (JP) | 2019-02-13 | — | — | EP | disclosed |
| US-10182993-B2 | Compositions for colonic delivery of drugs | PATHEON SOFTGELS INC. (US) | 2019-01-22 | — | — | US | disclosed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-2465539-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-20180147189-A1 | ADMINISTRATION REGIMEN FOR THERAPEUTIC AGENTS FOR ATAXIA IN SPINOCEREBELLAR DEGENERATION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-3315128-A1 | DOSING REGIMEN OF THERAPEUTIC AGENT FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-05-02 | — | — | EP | disclosed |
| CN-107735089-A | Dosing regimen for a therapeutic agent for ataxia in spinocerebellar degeneration | 橘生药品工业株式会社 | 2018-02-23 | — | — | CN | disclosed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | disclosed |
| US-9844506-B2 | Compositions and methods for affecting mood states | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9796751-B2 | Glycyrrhetinic acid derivative and use thereof | INI CORPORATION (JP) | 2017-10-24 | — | — | US | disclosed |
| CN-102223880-B | Oral quick disintegrating tablet and its preparation method | 田边三菱制药株式会社 | 2017-04-26 | — | — | CN | disclosed |
| CN-103919742-B | Orally Rapidly Disintegrating Tablet And Process For Producing Same | 田边三菱制药株式会社 | 2017-04-12 | — | — | CN | disclosed |
| US-20170079908-A1 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20160376303-A1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | INI CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| EP-3086789-A1 | OPIOID ANTAGONIST FORMULATIONS | Purdue Pharma L.P. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9480642-B2 | Compositions and methods for affecting mood states | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160287525-A1 | COMPOSITIONS FOR COLONIC DELIVERY OF DRUGS | BANNER LIFE SCIENCES LLC | 2016-10-06 | — | — | US | disclosed |
| EP-3075738-A1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | INI CORPORATION (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2465540-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-9446055-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20160243107-A1 | Opioid Antagonist Formulations | PURDUE PHARMA L.P. | 2016-08-25 | — | — | US | disclosed |
| EP-3023109-A1 | ORALLY DISINTEGRATING TABLET | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136091-A1 | Orally Disintegrating Tablet | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20160136087-A1 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9314454-B2 | Oral cavity disintegrating tablet and method of producing the same | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-9295637-B2 | Compositions and methods for affecting mood states | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| CN-105377303-A | Orally disintegrating tablet | SANWA KAGAKU KENKYUSHO CO | 2016-03-02 | — | — | CN | disclosed |
| CN-103096881-B | Containing the film preparation of medicine with unpleasant taste | KYUKYU PHARMACEUTICAL CO.,LTD. (JP) | 2015-09-30 | — | — | CN | disclosed |
| WO-2015100197-A1 | OPIOID ANTAGONIST FORMULATIONS | PURDUE PHARMA L.P. (US) | 2015-07-02 | — | — | WO | disclosed |
| EP-2808013-A1 | Orally rapidly disintegrating tablet and process for producing same | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-8900602-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| WO-2014160069-A1 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140271805-A1 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| CN-103919742-A | Orally Rapidly Disintegrating Tablet And Process For Producing Same | MITSUBISHI TANABE PHARMA CORP | 2014-07-16 | — | — | CN | disclosed |
| US-20140170157-A1 | METHOD OF SELECTING THERAPEUTIC INDICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-06-19 | — | — | US | disclosed |
| EP-2233129-B1 | ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME | SAWAI SEIYAKU KK (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| CN-103096881-A | Film preparation containing medicament with unpleasant taste | KYUKYU YAKUHIN KOGYO KK | 2013-05-08 | — | — | CN | disclosed |
| CN-102988318-A | Orally rapidly disintegrating tablet and process for producing same | MITSUBISHI TANABE PHARMA CORP | 2013-03-27 | — | — | CN | disclosed |
| US-8378112-B2 | Glycyrrhetinic acid derivative and use thereof | INI CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| EP-2543366-A1 | FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE | Kyukyu Pharmaceutical Co., Ltd. (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20120328675-A1 | FILM PREPARATION CONTAINING MEDICAMENT WITH UNPLEASANT TASTE | KOWA CO., LTD. (JP) | 2012-12-27 | — | — | US | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| CN-102223880-A | Oral quick disintegrating tablet and its preparation method | MITSUBISHI TANABE PHARMA CORP | 2011-10-19 | — | — | CN | disclosed |
| EP-2368544-A1 | ORALLY RAPIDLY DISINTEGRATING TABLET, AND PROCESS FOR PRODUCING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-20110229570-A1 | ORALLY RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR PRODUCING SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110190354-A1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | INI CORPORATION (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20100278930-A1 | ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2233129-A1 | ORAL CAVITY DISINTEGRATING TABLET AND METHOD OF PRODUCING THE SAME | Sawai Pharmaceutical Co., Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20100209520-A1 | ORAL PHARMACEUTICAL PREPARATION FOR COLON-SPECIFIC DELIVERY | AMATERASPHARMA INC. (JP) | 2010-08-19 | — | — | US | disclosed |
| CN-101677958-A | Oral pharmaceutical formulation for colon-specific delivery | TEIKOKU SEIYAKU KK | 2010-03-24 | — | — | CN | disclosed |
| EP-2143424-A1 | ORAL PHARMACEUTICAL PREPARATION FOR COLON-SPECIFIC DELIVERY | TEIKOKU SEIYAKU CO., LTD. (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUG-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2009-05-07 | — | — | US | disclosed |
| US-7462595-B2 | Methods for treating cancer-related fatigue | TRH THERAPEUTICS LLC | 2008-12-09 | — | — | US | disclosed |
| US-7323039-B2 | Method for preparing microsphere | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-29 | — | — | US | disclosed |
| EP-1793842-A2 | TREATMENT FOR CANCER-RELATED FATIGUE | Winokur, Andrew (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1713457-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20060096715-A1 | Method for preparing microsphere | TANABE SEIYAKU CO., LTD. | 2006-05-11 | — | — | US | disclosed |
| US-20060063703-A1 | Methods for treating cancer-related fatigue | TRH THERAPEUTICS LLC | 2006-03-23 | — | — | US | disclosed |
| WO-2006031980-A2 | TREATMENT FOR CANCER-RELATED FATIGUE | WINOKUR ANDREW (US) | 2006-03-23 | — | — | WO | disclosed |
| US-7011776-B2 | Method and apparatus for preparing microspheres | TANABE SEIMAN CO., LTD. (JP) | 2006-03-14 | — | — | US | disclosed |
| WO-2005077343-A9 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX DELBRUECK CENTRUM (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005077343-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2005-08-25 | — | — | WO | disclosed |
| CN-1430506-A | Process for producing microsphere | TANABE SEIYAKU CO (JP) | 2003-07-16 | — | — | CN | disclosed |
| US-20030094715-A1 | Method for preparing microsphere | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-20030075817-A1 | Process for producing microsphere | TANABE SEIYAKU CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1277787-A1 | METHOD FOR PREPARING MICROSPHERE | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1277465-A1 | PROCESS FOR PRODUCING MICROSPHERE | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020160961-A1 | Compositions for the treatment of the catabolic state of prolonged critical illness | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | disclosed |
| EP-1200111-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2002-05-02 | — | — | EP | disclosed |
| WO-2000074702-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000074702-A1 | COMPOSITIONS FOR THE TREATMENT OF THE CATABOLIC STATE OF PROLONGED CRITICAL ILLNESS | NOVO NORDISK A/S (DK) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023068-A1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | ITPR2, ATP2A2, ORAI1 | TRHR 877/4885 |
| US-20160136087-A1 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES | NOS1, NOS2, NOS3 | TRHR 1612/4885 |
| US-20170079908-A1 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES | NOS1, NOS2, NOS3 | TRHR 1612/4885 |
| US-20190240221-A1 | COMPOSITION COMPRISING COMBINATION OF TRH ANALOG WITH ARUNDIC ACID, AND PHARMACEUTICALLY ACCEPTABLE SALT OF ARUNDIC ACID | TRHR, TRHDE, CRH | TRHR 1/4885 |
| US-11510914-B2 | Agent for inhibiting rise in intraneuronal calcium concentration | ITPR2, ATP2A2, ORAI1 | TRHR 877/4885 |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | TRHR 4548/4885 |
| US-12582606-B2 | Tablet and method for producing tablet | GRHPR, RCC1, KIT | TRHR 1550/4885 |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | TRHR 4548/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | TRHR 64/4885 |
| US-10828303-B2 | Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid | TRHR, TRHDE, CRH | TRHR 1/4885 |
| US-20140170157-A1 | METHOD OF SELECTING THERAPEUTIC INDICATIONS | TSG101, TPMT, HLA-DRB1 | TRHR 2637/4885 |
| US-20180147189-A1 | ADMINISTRATION REGIMEN FOR THERAPEUTIC AGENTS FOR ATAXIA IN SPINOCEREBELLAR DEGENERATION | TSHR, ATXN10, ATXN2 | TRHR 4/4885 |
| US-20160376303-A1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | GRHPR, GYPA, GPBAR1 | TRHR 819/4885 |
| US-20140271805-A1 | COMPOSITIONS AND METHODS FOR AFFECTING MOOD STATES | NOS1, NOS2, NOS3 | TRHR 1612/4885 |
| US-20110190354-A1 | GLYCYRRHETINIC ACID DERIVATIVE AND USE THEREOF | GJA1, GJB2, GAP43 | TRHR 3415/4885 |
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | APP, PSEN2, PSEN1 | TRHR 4496/4885 |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | STING1, CGAS, IRF3 | TRHR 3663/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | TRHR 3237/4885 |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | TRHR 3643/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | TRHR 8/4885 |
| US-20020160961-A1 | Compositions for the treatment of the catabolic state of prolonged critical illness | CRH, CRHBP, TRHDE | TRHR 7/4885 |
| US-20060063703-A1 | Methods for treating cancer-related fatigue | CRH, TRHR, SSTR4 | TRHR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.